Skip to content
The Biopharma Sustainability Roundtable published a guidance document which expands on strategic thinking and planning of biotechnology and pharma investor Environmental, Social, and Governance […]
How biopharma can better communicate about ESG Read More »
The U.S. Federal Trade Commission (FTC) announced last week that it will investigate the “prescription drug middleman industry,” demanding information and records regarding the
FTC will investigate six largest pharmacy benefit managers Read More »
One of the key lessons of the COVID-19 pandemic has been the need to strengthen government support for biotechnology, with direct funding but also
Top officials share a key COVID lesson: Governments must support biotech Read More »
Regenerative farming is not only beneficial for soil and crops but also improves the nutritional value of food, a recent study shows. Biotechnology can
Study reveals nutrition benefits of regenerative farming; biotech is helping Read More »
James A. Geraghty, a board director of five NASDAQ-listed biotech companies and author, joins a conversation with Paul Hastings, CEO of Nkarta Therapeutics and
‘Inside the Orphan Drug Revolution’ author speaks today – read an excerpt of the book Read More »
Legislation to reauthorize Food and Drug Administration (FDA) user fee agreements passed the House with bipartisan support Wednesday, and the Senate is expected to
House votes to reauthorize FDA user fees; Senate’s up next Read More »
A May 16 letter signed by 125 patient advocacy groups urges congressional leaders to restore the access to COVID treatment for the uninsured that
Patient groups urge lawmakers to restore access to COVID treatment Read More »
Novavax’s two-dose vaccine against COVID-19 moved closer to Emergency Use Authorization (EUA) from the Food and Drug Administration yesterday when the FDA’s Vaccines and
FDA advisory committee recommends EUA for Novavax COVID vaccine Read More »
Moderna announced yesterday that doses have been given to participants in a Phase 3 clinical trial of seasonal influenza vaccines using the revolutionary mRNA
Moderna launches Phase 3 trial of mRNA flu vaccine candidate Read More »
Projected Medicare Part D costs in 2022 are slightly lower than in 2021 and slower growth in overall drug prices is one of the
Medicare trustees say they expect Part D costs to fall in 2022 Read More »
